Patents by Inventor Brian E. Toki

Brian E. Toki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7091186
    Abstract: Compounds of the formulae LAn-Z-X—WwD and BZ-X—WwD wherein: D is a drug moiety; L is a ligand; B is a blocking group; A is an optional acyl unit; Z is an amino acid or a peptide residue; X is an aminobenzyl ether self-immolative spacer group; W is an optional second self-immolative group; n is an integer of 0 or 1; and w is an integer of 0 or 1, and compositions of said compounds with pharmaceutically acceptable carrier, diluent and/or excipient, and methods of delivery the drug D via the compounds.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: August 15, 2006
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter D. Senter, Brian E. Toki
  • Patent number: 6884869
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: April 26, 2005
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter D. Senter, Brian E. Toki, Svetlana Doronina
  • Publication number: 20040157782
    Abstract: Pentapeptide compounds are disclosed. The compounds have biological activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide moieities, as well as precursors thereof are also disclosed. For example, precursors having a reactive linker that can serve as a reaction site for joining to a targeting agent, e.g., an antibody, as disclosed.
    Type: Application
    Filed: March 29, 2004
    Publication date: August 12, 2004
    Inventors: Svetlana Doronina, Peter D. Senter, Brian E. Toki
  • Publication number: 20040018194
    Abstract: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.
    Type: Application
    Filed: May 28, 2003
    Publication date: January 29, 2004
    Inventors: Joseph A. Francisco, Grant Risdon, Alan F. Wahl, Clay Siegall, Peter D. Senter, Sveltana Doronina, Brian E. Toki
  • Publication number: 20030130189
    Abstract: Compounds of the formulas
    Type: Application
    Filed: September 23, 2002
    Publication date: July 10, 2003
    Inventors: Peter D. Senter, Brian E. Toki
  • Publication number: 20030096743
    Abstract: Compounds of the formulae
    Type: Application
    Filed: September 24, 2001
    Publication date: May 22, 2003
    Applicant: Seattle Genetics, Inc.
    Inventors: Peter D. Senter, Brian E. Toki